Drugs / [177Lu]Lu-DWJ155
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07660055 | Jun 2026 → May 2032 expected | breast cancer, gastroesophageal cancer, non-small cell lung carcinoma, urinary bladder cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-DWJ155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660055 ↗ |
| Modality | Other / unclassified | “Radioligand therapy” NCT07660055 ↗ |